Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: A preliminary study of the correlations between quantitative parameters and clinical stage

2013 ◽  
Vol 39 (4) ◽  
pp. 940-948 ◽  
Author(s):  
Dechun Zheng ◽  
Yunbin Chen ◽  
Ying Chen ◽  
Luying Xu ◽  
Weibo Chen ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Clinical Stage ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Quantitative Parameters ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Preliminary Study ◽  
Contrast Enhanced Mri

scholarly journals Comparison of quantitative parameters in cervix cancer measured by dynamic contrast-enhanced MRI and CT

2010 ◽  
Vol 63 (6) ◽  
pp. 1601-1609 ◽  
Author(s):  
Cheng Yang ◽  
Walter M. Stadler ◽  
Gregory S. Karczmar ◽  
Michael Milosevic ◽  
Ivan Yeung ◽  
...  
Keyword(s):  
Cervix Cancer ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Quantitative Parameters ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri

Dynamic Contrast-Enhanced MRI Predicts PTEN Protein Expression which can Function as a Prognostic Measure of Progression-free survival in NPC patients.

2021 ◽  
Author(s):  
Gang Wu ◽  
Weiyuan Huang ◽  
Wenzhu Li ◽  
Yu Wu ◽  
Qianyu Yang ◽  
...  
Keyword(s):  
Clinical Stage ◽  
Progression Free Survival ◽  
Free Survival ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Worse Prognosis ◽  
Contrast Enhanced Mri

Abstract Objectives: The objective of our study was to investigate whether a phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression was associated with dynamic contrast-enhanced MRI (DCE-MRI) parameters and prognosis in nasopharyngeal carcinoma (NPC).Methods: Two hundred and forty-five (245) patients with NPC who underwent pretreatment biopsy, PTEN immunohistochemistry of biopsy, and radical intensity-modulated radiation therapy (IMRT) with or without chemotherapy were included. Tumor segmentations were delineated on pretreatment MRI manually. The pharmacokinetic parameters (Ktrans, Kep, Ve, and Vp) derived from dynamic contrast-enhanced MRI (DCE-MRI) using the extended Toft’s model within the tumor segmentations were estimated. The following demographics and clinical features were assessed and correlated against each other: gender, age, TNM stage, clinical-stage, Epstein-Barr virus (EBV), pathological type, progression-free survival (PFS), and prognosis status. DCE parameter evaluation and clinical feature comparison between the PTEN positive and negative groups was performed and correlation between PTEN expression with the PFS and prognosis status using Cox regression for survival analysis was assessed.Results: A significantly lower Ktrans and Kep were found in NPC tumors in PTEN negative patients than in PTEN positive patients. Ktrans performed better than Kep in detecting PTEN expression with the ROC AUC of 0.752. PTEN negative was associated with later TNM stage, later clinical-stage, shorter PFS, and worse prognosis. Moreover, N stage, pathological type, Kep, and prognostic status can be considered as independent variables in discrimination of PTEN negative expression in NPCs. Conclusions: PTEN negative indicated a shorter PFS and worse prognosis than PTEN positive in NPC patients. Ktrans and Kep derived from DCE-MRI, which yielded reliable capability, should be considered as novel image markers that are correlated with PTEN expression and may be used to predict PTEN expression noninvasively. Combined radiological and clinical features can improve the performance of the classification of PTEN expression.

Sign in / Sign up

Export Citation Format

Share Document